Application of a compound in preparing a drug for preventing or treating ischemic stroke
Compound C148-0670 forms a variety of dosage forms by combining with pharmaceutical excipients to prevent and treat ischemic stroke, solving the problem of narrow time window and bleeding risk of existing treatment methods, significantly improving the nerves of rats with cerebral ischemic Functional and cognitive ability provide a safe and effective treatment plan.
Patent Information
- Application Number
- CN202110838869.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-07-23
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2041-07-23
AI Technical Summary
The existing anti-stroke drug treatment methods are limited, especially the treatment time window for ischemic stroke is narrow and there is a risk of bleeding, which cannot effectively prevent and treat neurological damage caused by cerebral ischemia.
Compound C148-0670 is used to prepare drugs for preventing and treating ischemic stroke and post-stroke nerve repair, and forms pharmaceutical compositions of different dosage forms for oral administration by combining with pharmaceutically acceptable salts, carriers or excipients. , injection or dermatological mucosal route for treatment and prevention in acute, subacute and recovery periods.
Compound C148-0670 significantly improved neurobehavioral disorders in rats with cerebral ischemic, reduced cerebral infarction rate, promoted the recovery of cognitive behavioral abilities, and provided a safe and effective anti-stroke treatment plan.
Smart Images

Figure CN115671104B_ABST
Abstract
Description
Technical Field
[0001] The present invention mainly relates to the use of a compound C148-0670 in preparing a drug for preventing and / or treating ischemic stroke, and belongs to the field of medical technology. Background Art
[0002] Stroke is a cerebrovascular disease characterized by focal neurological damage caused by sudden rupture of cerebral blood vessels or blockage of cerebral blood vessels, which results in the inability of blood to flow into the brain. Stroke has become the second leading cause of death in the world, accompanied by high disability and morbidity rates. It has now become the leading cause of death among Chinese residents. Acute stroke patients are often accompanied by serious sequelae, which affect the patient's quality of life and bring huge economic burdens to the family and society. Stroke is divided into ischemic stroke, hemorrhagic stroke and transient ischemic attack. Ischemic stroke is the main type of stroke. In 2018, 81.9% of stroke hospitalized patients suffered from ischemic stroke, mainly due to insufficient cerebral blood flow caused by embolism or arteriosclerosis, which deprives the brain of oxygen, glucose and other essential nutrients, thereby causing further damage to the brain parenchyma. The pathogenesis and pathological process of stroke are complex, including calcium overload, excitotoxic injury, oxidative stress injury, inflammatory injury, etc.
[0003] At present, clinical anti-stroke drugs and intervention measures are limited, mainly intravenous thrombolytic therapy and intravascular thrombectomy. Intravenous thrombolytic therapy uses tissue plasminogen activator (t-PA), which has a narrow treatment time window of only 4.5 hours, limiting its use in 95% of clinical patients. In addition, t-PA has a high risk of bleeding, and a small number of patients are still at risk of hemorrhagic transformation after receiving t-PA thrombolysis. Intravascular thrombectomy has few indications. Therefore, the above measures can only benefit a small number of clinical patients, and the development of safe and effective new drugs for the treatment of stroke has great social significance.
[0004] The Pubchem number of compound C148-0670 is C148-0670, and the molecular formula is: C 29 H 36 N4O5S, with the structural formula as follows: So far, there has been no report on the pharmacological effect of the compound in anti-stroke, and there has been no report on the effect of C148-0670 in the preparation of anti-stroke drugs.
[0005] Summary of the invention
[0006] The technical problem solved by the present invention is to provide an application of a compound C148-0670 in the preparation of a drug for preventing and treating ischemic stroke and post-stroke nerve repair, thereby providing an effective solution for the treatment of cerebral ischemia.
[0007] To this end, the present invention provides the following technical solutions:
[0008] The first aspect of the technical solution of the present invention provides the use of compound C148-0670 as shown in Formula I in the preparation of drugs for preventing and treating ischemic stroke and post-stroke neural repair.
[0009]
[0010] Furthermore, the stroke is acute ischemic stroke, transient ischemic attack and chronic cerebral ischemia.
[0011] Furthermore, the effects of the compound C148-0670 include both therapeutic and preventive effects on cerebral ischemia.
[0012] Furthermore, the treatment of cerebral ischemia is the treatment of acute ischemic stroke, transient ischemic attack and chronic cerebral ischemia;
[0013] Furthermore, the prevention of cerebral ischemia is the prevention of acute ischemic stroke, transient ischemic attack and chronic cerebral ischemia;
[0014] Furthermore, the therapeutic effect of compound C148-0670 on cerebral ischemia is characterized by targeting treatment at any stage after the acute attack, including the acute phase, subacute phase, and recovery phase;
[0015] Furthermore, the preventive effect of compound C148-0670 on cerebral ischemia is characterized by targeting high-risk populations without acute symptoms, as well as patients who have already suffered cerebral ischemia and received treatment, with the purpose of avoiding recurrence.
[0016] The second aspect of the technical solution of the present invention provides an application of a pharmaceutical composition in the preparation of a drug for preventing and / or treating stroke and post-stroke neurorepair, characterized in that the pharmaceutical composition contains the compound C148-0670 described in the first aspect and a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier or excipient.
[0017] The pharmaceutical composition is selected from oral preparations, injection dosage forms or skin and mucosal dosage forms.
[0018] The oral preparations include tablets, capsules, sustained-release agents, controlled-release agents, pills, powders, granules, solutions, emulsions, and suspensions; the injectable dosage forms include intramuscular injection, intravenous injection, and intravenous infusion; the skin and mucosal administration dosage forms include external solutions, lotions, liniments, ointments, plasters, pastes, patches, eye drops, nasal drops, eye ointments, gargles, sublingual tablets, adhesive sheets, and patches.
[0019] The pharmaceutical composition can be prepared according to methods known in the art. The compound C148-0670 of the invention can be combined with one or more pharmaceutically acceptable solid or liquid excipients and / or auxiliary materials to prepare any dosage form for human or animal use. The content of the compound of the invention in its pharmaceutical composition is usually 0.1-99%.
[0020] The compound of the present invention or the pharmaceutical composition containing it can be administered in the form of a unit dose, and the administration route can be gastrointestinal or parenteral, such as oral, intravenous, intramuscular, subcutaneous, nasal, oral mucosa, eyes, lungs and respiratory tract, skin, vagina, rectum, etc.
[0021] The drug combination dosage forms include oral preparations, injection dosage forms and skin mucosal dosage forms.
[0022] The oral preparations include tablets, capsules, sustained-release agents, controlled-release agents, pills, powders, granules, solutions, emulsions, and suspensions; the injectable dosage forms include intramuscular injection, intravenous injection, and intravenous infusion; the skin and mucosal administration dosage forms include external solutions, lotions, liniments, ointments, plasters, pastes, patches, eye drops, nasal drops, eye ointments, gargles, sublingual tablets, adhesive sheets, and patches.
[0023] The dosage form can be a liquid dosage form, a solid dosage form or a semisolid dosage form. Liquid dosage forms can be solutions (including true solutions and colloidal solutions), emulsions (including o / w types, w / o types and multiple emulsions), suspensions, injections (including water injections, powder injections and infusions), eye drops, nasal drops, lotions and liniments, etc.; solid dosage forms can be tablets (including ordinary tablets, enteric-coated tablets, lozenges, dispersible tablets, chewable tablets, effervescent tablets, orally disintegrating tablets), capsules (including hard capsules, soft capsules, enteric-coated capsules), granules, powders, micropills, dropping pills, suppositories, films, patches, aerosols (powders), sprays, etc.; semisolid dosage forms can be ointments, gels, pastes, etc.
[0024] The compound of the present invention can be made into common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle drug delivery systems.
[0025] In order to prepare the compound of the present invention into tablets, various excipients known in the art can be widely used, including diluents, binders, wetting agents, disintegrants, lubricants, and glidants. The diluent may be starch, dextrin, sucrose, glucose, lactose, mannitol, sorbitol, xylitol, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, calcium carbonate, etc.; the wetting agent may be water, ethanol, isopropanol, etc.; the binder may be starch slurry, dextrin, syrup, honey, glucose solution, microcrystalline cellulose, acacia gum slurry, gelatin slurry, sodium carboxymethyl cellulose, methyl cellulose, carboxypropyl methyl cellulose, ethyl cellulose, acrylic resin, carbomer, polyvinyl pyrrolidone, polyethylene glycol, etc.; the disintegrant may be dry starch, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, sodium bicarbonate and citric acid, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfate, etc.; the lubricant and glidant may be talc, silicon dioxide, stearate, tartaric acid, liquid paraffin, polyethylene glycol, etc.
[0026] The compound of the present invention can be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.
[0027] In order to prepare the dosing unit into a capsule, C148-0670 can be mixed with a diluent and a glidant, and the mixture can be directly placed in a hard capsule or a soft capsule. C148-0670 can also be first prepared into granules or pellets with a diluent, a binder, and a disintegrant, and then placed in a hard capsule or a soft capsule. The diluents, binders, wetting agents, disintegrants, and glidants used to prepare tablets of the compound of the present invention can also be used to prepare capsules of the compound of the present invention.
[0028] To prepare the compound of the present invention into an injection, water, ethanol, isopropanol, propylene glycol or a mixture thereof can be used as a solvent and an appropriate amount of a solubilizer, a cosolvent, a pH adjuster, and an osmotic pressure regulator commonly used in the art can be added. The solubilizer or cosolvent can be poloxamer, lecithin, hydroxypropyl-B-cyclodextrin, etc.; the pH adjuster can be phosphate, acid salt, hydrochloric acid, sodium hydroxide, etc.; the osmotic pressure regulator can be sodium chloride, mannitol, glucose, phosphate, acetate, etc. If a lyophilized powder injection is prepared, mannitol, glucose, etc. can also be added as a support. In addition, if necessary, a colorant, a preservative, a fragrance, a flavoring agent or other additives can also be added to the pharmaceutical preparation.
[0029] In order to achieve the purpose of medication and enhance the therapeutic effect, the drug or pharmaceutical composition of the present invention can be administered by any known method of administration. The dosage of the pharmaceutical composition of the compound of the present invention can vary widely according to the nature and severity of the disease to be prevented or treated, the individual conditions of the patient or animal, the route of administration and the dosage form. Generally speaking, the daily suitable dosage range of the compound of the present invention is 0.001-400 mg / kg body weight. The above dosage can be administered in one dosage unit or divided into several dosage units, depending on the doctor's clinical experience and the dosage regimen including the use of other treatment means.
[0030] The compound or composition of the present invention can be taken alone or in combination with other therapeutic drugs or symptomatic drugs. When the compound of the present invention has a synergistic effect with other therapeutic drugs, its dosage should be adjusted according to the actual situation.
[0031] The beneficial effect of the present invention is that the present invention investigated the anti-ischemic effect of compound C148-0670 through in vitro and in vivo ischemia-reperfusion models. The results showed that the in vitro oxygen-glucose deprivation / reoxygenation neuronal injury model showed that compound C148-0670 had a significant protective effect on neurons. In vivo experiments used a rat cerebral ischemia-reperfusion model, and the injection of compound C148-0670 significantly improved the neurobehavioral disorders of rats with cerebral ischemia; reduced the cerebral infarction rate of rats with cerebral ischemia; and promoted the recovery of cognitive behavioral abilities of rats with cerebral ischemia-reperfusion. Compound C148-0670 provides an effective solution for the prevention and treatment of stroke. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 Effects of compound C148-0670 on the SH-SY5Y cell OGD / R model Control group; oxygen-glucose deprivation / reoxygenation model group; different concentrations of drug test groups: C148-0670 0.01μM group, C148-0670 0.1μM group, C148-0670 1μM group, C148-0670 0.01μM group, C148-0670 10μM group; positive drug Eda1μM group. ### Compared with the control group, p<0.001; ***Compared with the model group, p<0.001.
[0033] Figure 2 Effects of compound C148-0670 on Zea Longa scores in rats Sham operation group; middle cerebral artery occlusion / reperfusion (MCAO / R) model group prepared by suture embolism; drug administration groups: C148-0670 low-dose group (2.5 mg / kg group), C148-0670 medium-dose group (5 mg / kg group), C148-0670 high-dose group (10 mg / kg group); positive drug edaravone group (10.0 mg / kg); #### Compared with the sham operation group, p<0.0001; ***Compared with the model group, p<0.001; ****Compared with the model group, p<0.0001.
[0034] Figure 3 Effect of compound C148-0670 on cerebral infarction rate in rats The grouping is the same as in Example 1, #### Compared with the sham operation group, p<0.0001; *compared with the model group, p<0.05; ***compared with the model group, p<0.001; ****compared with the model group, p<0.0001.
[0035] Figure 4 Effects of compound C148-0670 on cognitive and behavioral abilities in the recovery period of rats with cerebral ischemia-reperfusion The experimental groups were the same as those in Example 1; D2: discrimination index between the same objects on the second day of the experiment; D3: discrimination index between different objects on the third day of the experiment; (A) Experimental schematic diagram; (B) Comparison of discrimination ability between the second and third days in each group; *p<0.05 compared with D2; **p<0.01 compared with D2; ***p<0.001 compared with D2; (C) Comparison of novel object discrimination ability among the test groups on the third day; ### Compared with the sham operation group, p<0.001; **Compared with the model group, p<0.01; *Compared with the model group, p<0.05; DETAILED DESCRIPTION
[0036] In order to make the purpose, technical solutions and advantages of the present invention more clear, the present invention will be further described in detail below with reference to the accompanying drawings, but the present invention is not limited to the illustrated implementation scope.
[0037] Example 1: Effect of compound C148-0670 on SH-SY5Y cell oxygen glucose deprivation / reoxygenation model
[0038] Experimental materials: SH-SY5Y human neuroblastoma cell line cells were purchased from the National Experimental Cell Resource Sharing Platform. Compound C148-0670 and positive drug edaravone were purchased from Shanghai Taosu Biochemical Technology Co., Ltd.
[0039] Experimental groups: control group, oxygen glucose deprivation / reoxygenation (OGD / R) group, OGD / R+0.01μM C148-0670, OGD / R+0.1μM C148-0670, OGD / R+1μM C148-0670, OGD / R+10μM C148-0670, OGD / R+1μM edaravone group, cell independent experiments were repeated 8 times, n=8
[0040] OGD / R model: SH-SY5Y cells were grown at 3×10 4 The cells were inoculated into a 96-well culture plate at a density of 100 μL / mL. After culturing for 24 hours, the cells were washed once with PBS and 100 μL of Earle's solution without glucose was added to each well. The culture plate was placed in an anoxic chamber and pure N2 was continuously introduced into the chamber at a low flow rate until the oxygen meter reading dropped below 0.5% to confirm that the oxygen was emptied. The air inlet and outlet were clamped and the anoxic chamber was transferred to a 37°C incubator for culture. SH-SY5Y cells were hypoxic for 3 hours. At the same time, a group with only fluid replacement but no sugar and oxygen deficiency was set up as a control. After reoxygenation, the culture medium was replaced with normal serum-containing culture medium to terminate sugar deficiency, and the culture medium was restored to a normal oxygen content environment in a 37°C incubator as reperfusion. Cell survival rate was tested 24 hours after reoxygenation.
[0041] In vitro screening of compounds: After OGD, serum-containing medium containing different concentrations of compounds was added, with the concentrations being 0.01 μM, 0.1 μM, 1 μM, and 10 μM. MTT assay was performed after reoxygenation in a 37°C incubator for 24 h.
[0042] Determination of cell viability by MTT method: The cell survival rate was determined using the thiazolyl blue (MTT) assay. The cells were seeded onto a 96-well plate. After the corresponding treatment, 10 μL of MTT solution (5 mg / mL) was added to each well. The reaction was allowed to proceed at 37°C for 4 hours until blue-purple crystals appeared. Then 100 μL / well of the triple solution was added and incubated at 37°C for 8 hours to dissolve the formazan crystals. The optical density value (OD value) was measured at 570 nm using a microplate reader. The relative cell survival rate was calculated by taking the average value. Relative cell survival rate (%) = (OD value of the experimental group / OD value of the control group) × 100%.
[0043] Statistics and analysis: All data are The data were analyzed statistically using one-way analysis of variance (Prism 8.0), Dunnett's test was used as a post hoc test, and p < 0.05 was set as the standard of statistical difference.
[0044] Results: As shown in Table 1 and Figure 1The results of the OGD / R model test showed that compared with the blank group, oxygen-glucose deprivation and reoxygenation caused significant cell damage (70.0% ± 3.0%, p < 0.001). The edaravone-treated group significantly increased the cell survival rate compared with the model group (80.7% ± 3.6%, p < 0.001), indicating that the model can be used to evaluate drugs. Compared with the model group, 1μM and 10μM C148-0670 significantly increased the cell survival rate (89.1% ± 5.9%, p < 0.001; 82.3% ± 6.5%, p < 0.001), and 0.01μM and 0.1μM C148-0670 had no significant effect. The above results suggest that C148-0670 has anti-ischemic hypoxia therapeutic efficacy at 1μM and 10μM concentrations in vitro experimental detection.
[0045] Table 1 Effects of compound C148-0670 on SH-SY5Y cell OGD / R model
[0046]
[0047] ###, p<0.001 vs control group; ***p<0.001 vs model group. n=8.
[0048] Example 2: Effects of compound C148-0670 on neurobehavior in rats with cerebral ischemia-reperfusion
[0049] Experimental materials: SPF male SD rats, weighing 240-260 g, were purchased from Beijing Weitonglihua Animal Technology Co., Ltd., certificate number: SCXK (Beijing) 2019-0010. C148-0670 and positive drug edaravone were purchased from Shanghai Taosu Biochemical Technology Co., Ltd.
[0050] Experimental groups: 60 adult SD rats were randomly divided into sham control group, model group, C148-0670 low-dose group (2.5 mg / kg), medium-dose group (5 mg / kg), high-dose group (10 mg / kg), and positive drug edaravone group (10 mg / kg), with 10 rats in each group, and the drugs were dissolved in normal saline. Except for the sham group, all animals underwent MCAO surgery modeling, and the suture was removed after 90 minutes of ischemia for reperfusion. After the suture was removed, the C148-0670 and edaravone groups were immediately given the corresponding drug treatment through the tail vein, and the sham group and model group were given the same volume of solvent control saline.
[0051] Establishment of the animal model of cerebral ischemia-reperfusion: The middle cerebral artery occlusion / reperfusion (MCAO / R) model was prepared by suture embolization. Rats were anesthetized with isopentane and fixed on the operating table in a supine position. The neck was disinfected, and a 2-cm incision was made in the middle of the anterior neck. The subcutaneous soft tissue and muscle were bluntly separated to expose and separate the common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA). The ECA and its branches were ligated with No. 0 surgical thread, and artery clamps were placed before the bifurcation of the CCA and near the cranial end of the ICA. A micro-incision was made in the ECA 3 to 4 mm away from the bifurcation of the CCA. The artery clamp of ICA was loosened, and a special nylon thread (40 mm long, 0.26 mm in diameter) was inserted and pushed along the ICA to the beginning of the middle cerebral artery (MCA), about 18.5±0.5 mm, and stopped when resistance was encountered, resulting in blockage of the beginning of MCA. The nylon thread was fixed with No. 1 surgical thread, and the wound was covered with cotton balls soaked in saline. The rats were placed on an electric blanket for warmth. After 90 minutes (minutes, mins), the nylon thread was withdrawn and reperfused, and the wound was sutured. The sham operation group did not insert the nylon thread, and the rest of the operations were the same as the cerebral ischemia model group. During the experiment, the rats were placed on a temperature-controlled blanket, and the temperature controller was used to control the rat rectal temperature to maintain it in the range of 36.5-37°C.
[0052] Neurological function score: Neurobehavioral score is one of the most intuitive external indicators of animal brain damage. This study used the Zea Longa method for scoring. Animal behavioral scoring was observed 24 hours after surgery. Referring to the Longa method, the rat's tail was lifted about 1 foot off the ground and the condition of the two forelimbs was observed; the rat was placed on a horizontal ground and its shoulders were pushed to observe whether there was any difference in resistance on both sides; the rat was placed on the ground and its walking was observed. A five-point method (0-4 points) was used to score the behavior of each group. The higher the score, the more severe the neurobehavioral damage. (1) Those with completely normal behavior were scored 0 points; (2) Those with the tail lifted off the ground and the forelimb on the opposite side of the surgery rotated inward were scored 1 point; (3) The rat was placed on the ground and the resistance was checked by squeezing both sides with hands. Those with reduced resistance were scored 2 points; (4) The rat was placed on the ground and its walking was observed. Those who circled around the opposite side of the surgery were scored 3 points; (5) Those with extremely severe damage and no independent movement were scored 4 points.
[0053] Statistics and analysis: All data are The data were analyzed statistically using one-way analysis of variance (Prism 8.0), with Dunnett's test as the Posthoc test and p < 0.05 as the standard of statistical difference.
[0054] Results: As shown in Table 2 and Figure 2The results of the effect of compound C148-0670 on the Zea Longa score of rats showed that there was no motor disorder in the sham operation group, and the motor dysfunction of rats in the model group was obvious (3.15±0.67). Compared with the model group, the positive drug treatment group can significantly improve the motor ability of rats (1.42±0.52), with a significant difference (p<0.0001), indicating that this experimental system can be used to evaluate C148-0670 in the treatment of motor dysfunction caused by ischemic stroke. Compared with the model group, C148-06705.0mg / kg and 10.0mg / kg can significantly reduce the Zea Longa score of rats, which are 1.75±0.57 and 1.32±0.50, respectively, with statistical differences (p<0.001, 5mg / kg; p<0.0001, 10mg / kg). The above results suggest that C148-0670 at 5.0 mg / kg and 10.0 mg / kg is effective in treating movement disorders caused by ischemic stroke.
[0055] Table 2 Effects of compound C148-0670 on Zea Longa scores in rats
[0056]
[0057] ####, p<0.0001 vs sham operation group; ***p<0.001, ****p<0.0001 vs model group. n=7-10.
[0058] Example 3: Effect of compound C148-0670 on cerebral infarction rate in rats with cerebral ischemia-reperfusion
[0059] Determination of rat cerebral infarction rate: After the neurological function score was completed, the animals were immediately killed and the brain tissue was separated. After the brain tissue was separated, it was quickly placed in a -20℃ refrigerator and returned to room temperature after 30 minutes. The rat brain was placed in a slice mold, and after removing the olfactory bulb, cerebellum and lower brainstem, coronal slices were made at intervals of 2mm, for a total of 6 slices. Then the brain slices were quickly placed in 5ml of PBS solution containing 1% TTC, and incubated at 37℃ for 30 minutes in the dark. The brain slices were turned over every 5 minutes. After TTC staining, normal tissue was rose red, and infarcted tissue was not stained but white. The brain slices were taken out and fixed in 10% formalin. Each group of brain slices was arranged neatly and photographed for preservation. Imagepro Plus image analysis software was used for processing and statistics, and the infarction area of each brain slice was calculated. It was assumed that the infarction area of each brain slice was A, the area of each brain slice on the affected side was B, and the area of each slice on the healthy side was C. Infarction rate = (A1+A2+A3+A4+A5+A6) / (B1+B2+B3+B4+B5+B6+C1+C2+C3+C4+C5+C6)×100%.
[0060] Statistics and analysis: All data are The data were analyzed statistically using one-way analysis of variance (Prism 8.0), Dunnett's test was used as a post hoc test, and p < 0.05 was set as the standard of statistical difference.
[0061] Results: As shown in Table 3 and Figure 3 The results of the effect of compound C148-0670 on the cerebral infarction rate of rats showed that the cerebral infarction rate can directly reflect the degree of ischemia-reperfusion injury. TTC staining can make normal brain tissue red and the infarction area white. The one-way analysis of variance and Dunnett's test showed that compared with the model group (21.18% ± 2.54%), the infarction rate of rats in the positive drug group was significantly reduced (13.72% ± 4.182%), with statistical significance (p < 0.001), indicating that the experimental system is established and can be used to detect the pharmacodynamic evaluation of C148-0670 in the treatment of ischemic stroke. C148-0670 5.0mg / kg (15.56% ± 5.02%) and 10.0mg / kg (12.25% ± 4.58%) can reduce the infarction rate, with statistical difference (5.0mg / kg, p < 0.05; 10.0mg / kg, p < 0.0001); 2.5mg / kg group had no significant difference compared with the model group. The above results suggest that C148-0670 has the efficacy of treating ischemic stroke at a dose of 5.0mg / kg and 10.0mg / kg.
[0062] Table 3 Effect of compound C148-0670 on cerebral infarction rate in rats
[0063]
[0064] ####, p<0.0001 vs sham operation group; ***p<0.001, ****p<0.0001, vs model group. n=7-10.
[0065] Example 4: Effects of compound C148-0670 on cognitive and behavioral abilities in rats during the recovery period after cerebral reperfusion
[0066] Novel object recognition experiment: Novel object recognition is a delicate and sensitive behavioral method that uses the rodents' natural instinct to approach and explore novel objects to detect animal recognition memory. The novel object recognition experiment is used to detect the neurological repair and cognitive behavioral abilities of stroke rats during the recovery period. The day before the test, the test animals were placed in a square black-bottom box (40×40×45cm) and allowed to explore freely in the box for 5 minutes. On the second day, two identical objects were placed in the box, and the rats were put back in and allowed to explore freely in the box for 5 minutes. The number of times the rats touched the two novel objects in the box was recorded. On the third day, one of the old objects in the box was replaced with a new object that the test animal had never seen, and the rats were put back into the environment to explore freely for 5 minutes. The number of times the rats touched the two objects was recorded, and the percentage of rats' interest in new and old objects was compared. In order to avoid the influence of rat odor during the period, the box was wiped with 70% alcohol after each rat finished exploring. The time to explore new objects was recorded as T new , the time to explore new objects is recorded as T old .Discrimination index (DI) = (T new / (T new +T old )) is used to evaluate the exploration of the target object.
[0067] Statistics and analysis: All data are The discrimination index of each group on D2 and D3 was statistically analyzed by t-test, and the novel object discrimination ability of each group on the third day was statistically analyzed by one-way analysis of variance and Dunnett's test (Prism 8.0), with p < 0.05 as the statistical difference standard.
[0068] Results: Figure 4 The results of the effect of compound C148-0670 on the cognitive and behavioral abilities of rats in the recovery period after cerebral blood reperfusion showed that the rats in the model group did not show interest in exploring novel things, and there was a significant difference in the exploration of novel objects in the positive drug group (p<0.05), indicating that the experimental system is established and can be used to detect the pharmacodynamic evaluation of C148-0670 on the cognitive and behavioral abilities of rats in the recovery period after cerebral blood reperfusion. C148-067 5.0mg / kg (p<0.05) and 10.0mg / kg (p<0.01) were both statistically different; there was no significant difference in the 2.5mg / kg group. The above results suggest that C148-0670 promotes the recovery of cognitive and behavioral abilities in rats in the late stage of cerebral blood reperfusion at doses of 5.0mg / kg and 10.0mg / kg.
[0069] In summary, the present invention administered compound C148-0670 through in vivo and in vitro ischemia-reperfusion models, and found that compound C148-0670 can be used to prepare drugs for treating ischemic stroke and post-stroke repair, improve the survival rate of nerve cells, reduce the degree of brain tissue damage, and improve cognitive and behavioral abilities after stroke.
[0070] Therefore, compound C148-0670 has an anti-stroke effect. Compound C148-0670 is used as an active substance, used alone or / and combined with other pharmacologically active compounds and / or extracts to form a compound, and prepared into various dosage forms of anti-stroke drugs according to conventional preparation methods in the pharmaceutical field, or prepared into a compound preparation with other drugs, etc., to reduce adverse reactions in drug action while maintaining the therapeutic effect, which can provide an effective solution for the prevention and treatment of stroke.
[0071] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the scope of protection of the invention.
Claims
1. Use of the compound C148-0670 or a pharmaceutically acceptable salt thereof as shown in Formula I in the preparation of a drug for preventing and / or treating ischemic stroke:
2. According to the use of claim 1, the ischemic stroke is acute ischemic stroke.
3. Use of a pharmaceutical composition in the preparation of a drug for preventing and / or treating stroke, It is characterized in that The pharmaceutical composition contains the compound C148-0670 or a pharmaceutically acceptable salt thereof according to claim 1, and a pharmaceutically acceptable carrier.
4. The use according to claim 3, It is characterized in that The pharmaceutical composition is selected from oral preparations, injection preparations or skin and mucosal administration preparations.
5. The use according to claim 4, It is characterized in that The oral preparations include tablets, capsules, sustained-release agents, controlled-release agents, pills, powders, granules, solutions, emulsions, and suspensions; the injectable preparations include intramuscular injection preparations and intravenous injection preparations; the skin and mucosal administration preparations include lotions, liniments, ointments, plasters, pastes, patches, eye drops, nasal drops, gargles, sublingual tablets, adhesive sheets, and film preparations.
